<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153929</url>
  </required_header>
  <id_info>
    <org_study_id>1404-0002</org_study_id>
    <secondary_id>2019-002390-60</secondary_id>
    <nct_id>NCT04153929</nct_id>
  </id_info>
  <brief_title>A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.</brief_title>
  <official_title>A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to demonstrate a dose-relationship of BI 456906 on
      Glycosylated hemoglobin A1c (HbA1c)(absolute change) from baseline to 16 weeks relative to
      placebo in patients with Type 2 diabetes mellitus (T2DM).

      Secondary objectives are to assess the effect of BI 456906 on change in body weight. An
      open-label comparator (semaglutide) will allow for comparison of the effects against a pure
      Glucagon-like-peptide 1 receptor (GLP-1R) agonist.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in HbA1c from baseline to 16 weeks</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relative body weight change from baseline to 16 weeks (key secondary endpoint)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute body weight change from baseline to 16 weeks.</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in waist circumference from baseline to 16 weeks</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with 5% or greater body weight loss from baseline to 16 weeks</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with 10% or greater body weight loss from baseline to 16 weeks</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 7 (Semaglutide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 456906</intervention_name>
    <description>Injection</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_label>Dose group 5</arm_group_label>
    <arm_group_label>Dose group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_label>Dose group 4</arm_group_label>
    <arm_group_label>Dose group 5</arm_group_label>
    <arm_group_label>Dose group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Injection</description>
    <arm_group_label>Dose group 7 (Semaglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent in accordance with International conference
             on harmonization - Good clinical practice (ICH GCP) and local legislation.

          -  Male and female patients 18 years to 75 years (both inclusive) of age on the day of
             signing informed consent.

          -  Diagnosis of Type 2 diabetes mellitus (T2DM) at least 6 months prior to informed
             consent.

          -  Glycosylated hemoglobin A1c (HbA1c) 7.0%-10.0% (both inclusive).

          -  Treatment with a stable dose of metformin ≥ 1000mg/day for at least 3 months prior to
             screening.

          -  Body mass index (BMI) 25 kg/m2-50 kg/m2 (both inclusive) at screening.

          -  Women of childbearing potential and men able to father a child must be ready and able
             to use highly effective methods of birth control.

        Exclusion criteria:

          -  Patients with type 1 diabetes.

          -  Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists
             (including combination products) within 3 months prior to screening, or any previous
             exposure to BI 456906.

          -  Any additional oral anti-hyperglycemic medication beyond metformin within 3 months
             prior to screening.

          -  Use of insulin for glycemic control within 12 months prior to screening.

          -  Resting Heart Rate &gt;100 bpm or supine blood pressure ≥160/95 mmHg at screening.

          -  A marked baseline prolongation of QT/QTc interval or any other clinically significant
             Electrocardiogram (ECG) finding at screening.

          -  Body weight change of +/- 5% in the past 3 months or on anti-obesity therapies at any
             time during the 6 months prior to randomization.

          -  Treatment for any clinical condition that requires continuous oral pharmacotherapy
             during the trial except for metformin, anti-hypertensives, thyroid hormone
             replacement, lipid lowering, proton pump inhibitors, H2 blockers for Gastric
             esophageal reflux disease (GERD), analgesics, and inhaled respiratory medications,
             with a stable dose for at least 3 months prior to screening.

          -  Any suicidal behavior in the past 2 years, any suicidal ideation of type 4 or 5 in the
             Columbia-suicide severity rating scale (C-SSRS) in the past 3 months at screening.

          -  Chronic or relevant acute infections.

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

          -  Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Hsia</last_name>
      <phone>+001 (323) 588-1968</phone>
      <email>stanley.hsia@nritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cardona</last_name>
      <phone>+001 (305) 827-3335</phone>
      <email>jcardona@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Taylor</last_name>
      <phone>+001 (407) 654-2724</phone>
      <email>drtaylor@sensiblehealthcare.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>In-Quest Medical Research, LLC</name>
      <address>
        <city>Peachtree Corners</city>
        <state>Georgia</state>
        <zip>30071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Shah</last_name>
      <phone>+001 (770) 903-0148</phone>
      <email>DrShah@InQuestMed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solaris Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Butuk</last_name>
      <phone>+001 (203) 888-0123</phone>
      <email>pi@solarisclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Diabetes &amp; Endocrinology Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Wynne</last_name>
      <phone>+001 (785) 368-0428</phone>
      <email>awynne@stormontvail.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Smith</last_name>
      <phone>+001 (636) 387-5100</phone>
      <email>tsmith@studymetrix.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pullman</last_name>
      <phone>+001 (406) 723-1375</phone>
      <email>john.pullman@mercurystmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Earl</last_name>
      <phone>+001 (828) 345-5060</phone>
      <email>jearl@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rubino</last_name>
      <phone>+001 (919) 783-4895</phone>
      <email>jrubino@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Piedmont Healthcare</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Moran</last_name>
      <phone>+001 (704) 924-2105</phone>
      <email>joe.moran@piedmonthealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Cannon</last_name>
      <phone>+001 (910) 815-6108</phone>
      <email>kcannon@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Wilson</last_name>
      <phone>+001 (336) 768-8062</phone>
      <email>jwilson@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lillestol Research, LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lillestol</last_name>
      <phone>+001 (701) 232-7705</phone>
      <email>michael.lillestol@lillestolresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Rosenstock</last_name>
      <phone>+001 (972) 566-7799</phone>
      <email>juliorosenstock@dallasdiabetes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Javara Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Patel</last_name>
      <phone>+001 (346) 237-4868</phone>
      <email>rpatel1@priviamedicalgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Denham</last_name>
      <phone>+001 (210) 949-0122</phone>
      <email>ddenham@cttexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boden Institute of Obesity, Nutrition, Exercies and Eating Disorders</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Caterson</last_name>
      <phone>+61 2 86271937</phone>
      <email>ian.caterson@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunter Diabetes Centre</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Morbey</last_name>
      <phone>+61 2 4963 2323</phone>
      <email>clairemorbey@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elif Ekinci</last_name>
      <phone>61 3 9496 2250</phone>
      <email>elif.ekinci@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Hospital Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Toplak</last_name>
      <phone>+43 316 385 802 46</phone>
      <email>hermann.toplak@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH - Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Kautzky-Willer</last_name>
      <phone>+43-1-40400 43100</phone>
      <email>alexandra.kautzky-willer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Street Medical Clinic</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 4A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jones</last_name>
      <phone>250-383-3311</phone>
      <email>cookmed.research@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Clinical Research Inc. (Thornhill)</name>
      <address>
        <city>Concord</city>
        <state>Ontario</state>
        <zip>L4K 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Goldenberg</last_name>
      <phone>905-763-8660</phone>
      <email>ronald.goldenberg@LMC.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Wharton Medical Clinic Clinical Trials Inc.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Wharton</last_name>
      <phone>905 523 8134</phone>
      <email>wharton.sean@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Devonshire Clinical Research Inc.</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Heaton</last_name>
      <phone>519 537 8303</phone>
      <email>dr.heaton@tmginvestigators.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manna Research (Quebec)</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Vallieres</last_name>
      <phone>418-839-8572</phone>
      <email>gerald.vallieres@LMCmanna.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Medical Acadie</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Akhras</last_name>
      <phone>514 336 6655</phone>
      <email>ronald.cma@videotron.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edumed s.r.o</name>
      <address>
        <city>Broumov</city>
        <zip>55001</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alica Vesela</last_name>
      <phone>+420 491 413 238</phone>
      <email>alica.vesela@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital, Prague</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepan Svacina</last_name>
      <phone>+420 224 962 922</phone>
      <email>svacinas@lf1.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRC Gyogyszervizsgalo Kozpont Kft., Balatonfured</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Koranyi</last_name>
      <phone>+36 87 481616</phone>
      <email>laszlo.koranyi@drc.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Debrecen Hospital</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denes Pall</last_name>
      <phone>+36 52 255600</phone>
      <email>pall.denes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon-Jib Yoo</last_name>
      <phone>82 10 8994 0020</phone>
      <email>sjyoomt@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoung-Ah Kim</last_name>
      <phone>82 31 961 7136</phone>
      <email>kakimmd@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-Man Kim</last_name>
      <phone>82 2 2224 2575</phone>
      <email>dm@kdh.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Titchener</last_name>
      <email>liz@optimalclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research, Wellington</name>
      <address>
        <city>Newtown Wellington NZ</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Quinn</last_name>
      <phone>+64 4 801 0002 ext 754</phone>
      <email>dean@p3research.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Kamerbeek</last_name>
      <phone>64 7 579 0453</phone>
      <email>jackiek@p3research.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research Waikanae</name>
      <address>
        <city>Waikanae</city>
        <zip>5036</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Stubbs</last_name>
      <phone>64 4 901 2560</phone>
      <email>richards@p3research.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vita Longa Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Strozik-Krecichwost</last_name>
      <phone>+48 322029715</phone>
      <email>agnieszka.krecichwost@researchsolutions.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NBR Polska</name>
      <address>
        <city>Warsaw</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Klodawska</last_name>
      <phone>+48228407003</phone>
      <email>katarzyna.klodawska@nbrpolska.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Soto González</last_name>
      <phone>+34981178127</phone>
      <email>asotog10@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.A.P. Sardenya</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Brotons</last_name>
      <phone>34935674385</phone>
      <email>cbrotons@eapsardenya.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Jose Tinahones Madueno</last_name>
      <phone>+34677904110</phone>
      <email>fjtinahones@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Ampudia-Blasco</last_name>
      <phone>+34961973543</phone>
      <email>ampudia_fra@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang-Hua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Te Tu</last_name>
      <phone>+886 987712039</phone>
      <email>10836@cch.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung-Fu Chen</last_name>
      <phone>+886 975056090</phone>
      <email>0722cjf@adm.cgmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Ning Huang</last_name>
      <phone>+886-4-24739595 ext.34113</phone>
      <email>cshy049@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan,</city>
        <zip>71004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chwen-Yi Yang</last_name>
      <phone>++886-6-2812811 ext 55910</phone>
      <email>yangchwenyi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clifton Medical Centre, Rotherham</name>
      <address>
        <city>Rotherham</city>
        <zip>S65 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Capehorn</last_name>
      <phone>+44 0844 4773622</phone>
      <email>mcapehorn@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

